Dr. Dwight D. Blake, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 101
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
GA license 51117
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wellstar Kennestone Regional Medical Center Marietta, GA
- Piedmont Fayette Hospital Fayetteville, GA
Medical groups
- Rophe Adult and Pediatric Medicine (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 101
- Services billed
- 1,163
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 164 | 81 |
| Established patient office or other outpatient visit, 30-39 minutes | 87 | 53 |
| Annual alcohol misuse screening, 5 to 15 minutes | 55 | 55 |
| Annual depression screening, 5 to 15 minutes | 55 | 55 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 52 | 52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $369 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $369 |
|---|
| Food and Beverage | $369 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 9 companies. The companies reported $3,386,565 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are…
Amgen Inc. - A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company · Completed · NCT06047548 - A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Eli Lilly and Company · Completed · NCT06584916 - Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity
Genentech, Inc. - Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity
Hoffmann-la Roche Limited - A phase 2A randomized doubleblind sponsoropen placebocontrolled parallel group doseranging study of PF07976016 to assess safety and efficacy in adult participants with obesity
Pfizer Inc. - A parallel-group treatment, phase 2, double-blind study of once-weekly subcutaneous LY3457263 compared to placebo in participants with type 2 diabetes mellitus on a stable dose of tirzepatide or semaglutide who failed…
Eli Lilly and Company - A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company · Active, not recruiting · NCT05869903 - CT-388-104 OW/OB with T2D
Genentech, Inc. - A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.